XML 168 R152.htm IDEA: XBRL DOCUMENT
v3.20.4

Business Combination (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K) - Brooklyn Immunotherapeutics, LLC [Member] - Asset Purchase Agreement [Member] - IRX Therapeutic Inc [Member] | Nov. 07, 2018 USD ($)
--- | ---
Estimated fair value of future royalty payments | $ 870,000
Aggregate consideration on purchase of asset | 3,270,000
Fair value of the membership units | 2,400,000
Fair value of contingent consideration | $ 870,000

X
- Definition Estimated fair value of future royalty payments. + References No definition available. + Details
Name: | NTN_EstimatedFairValueOfFutureRoyaltyPayments
Namespace Prefix: | NTN_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value of the membership units. + References No definition available. + Details
Name: | NTN_FairValueOfMembershipUnits
Namespace Prefix: | NTN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of asset recognized arising from contingent consideration in a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6411-128476 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationAsset
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value of contingent consideration in a business combination that is classified in shareholders' equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=NTN_AssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=NTN_IRXTherapeuticIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |